Should You Buy Elevance Health Inc (ELV) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
BUY for a long-term beginner right now. ELV is trading around $341.85, well below the bulk of updated Wall Street price targets ($404–$431) after a volatile earnings reaction. While near-term technical momentum is still weak, the stock is closer to support ($328) than resistance ($354 pivot / $380), and fundamentals (Q4 growth + 2026 EPS floor guidance) and influential buying (Congress purchases, no sales) tilt the risk/reward positively for an impatient long-term investor deploying $50k–$100k.
Technical Analysis
Trend/momentum is still bearish-to-stabilizing. MACD histogram (-4.745) is below zero and negatively expanding, signaling downside momentum hasn’t fully reversed yet. RSI(6) at ~37 is weak (near oversold/washed-out territory) but not a confirmed reversal signal. Moving averages are converging (often a transition phase), suggesting the downtrend may be losing force but isn’t definitively turning up. Key levels: Support S1 ~$328 (then S2 ~$312); Resistance pivot ~$354, then R1 ~$380. With price ~$341.85, the stock is in the lower half of the range—better for long-term entry than chasing strength, but expect choppiness until it reclaims ~$354.
Analyst Ratings and Price Target Trends
Recent trend: predominantly more bullish. From early Jan 2026, several firms raised price targets (Barclays $404, Mizuho $413, Guggenheim $414, Wells Fargo $424, Wolfe upgrade with $425, Bernstein $431). The main counterpoint is Deutsche Bank’s Dec downgrade to Hold with a $320 target, and Morgan Stanley/BofA sitting more neutral. Wall Street pros: improving sentiment into 2026 (Medicare Advantage upside, potential sector turnaround, margin expansion narrative). Cons: ongoing regulatory/reimbursement uncertainty, utilization trends, and a ‘transition year’ framing that can keep the stock range-bound short term.
Wall Street analysts forecast ELV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELV is 392.07 USD with a low forecast of 320 USD and a high forecast of 431 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ELV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELV is 392.07 USD with a low forecast of 320 USD and a high forecast of 431 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 341.850
Current: 341.850
